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A b s t r a c t  
A series of substituted N-(Benzylidineamine)-3-cycloalkylidine-thiosemicarbazide derivatives have 
been synthesized, characterized and evaluated for their antifungal and antibacterial activities. The 
newly synthesized compounds were characterized by IR, NMR, Mass and elemental analysis. All 
compounds were tested for antifungal and antibacterial activities. The preliminary results revealed 
that some of the compounds exhibited promising antifungal activities. Among the tested compounds, 
compound 14 (MIC 8 øg/mL) and 25 (MIC 8 øg/mL) were the most effective against C. Tropicalis. 
Important SAR information was also gathered. Molecular modeling investigations showed that the 
active compounds may interact at the active site of the fungal cytochrome P450-dependent sterol 
14đ- demethylase (CYP51) in the sterol biosynthesis pathway.  
Keywords: N-(Benzylidineamine)-3-cycloalkylidine-thiosemicarbazide; Antifungal; Antibacterial; 
Molecular modeling; CYP51; Minimum inhibitory concentration. 
 
Introduction 
Thiosemicarbazide derivatives are important class of molecules with 
a large spectrum of biological properties. These compounds have 
been studied as anti-tubercular [1], anti-bacterial [2], anti-malarial [3], 
anti-leprosy [4], anti-parasitic [5] andantineoplastics [6].Antituberculer 
activity of cycloalkane analogues of thiosemicarbazidesis well 
documented [7].Cyclic analogues (cycloalkyl: cyclopentyl, 
cyclohexyletc.) were also found to be active against several species 
of candida (C. albicans and C. krusei) [8]. The effective role of 
azomethine linkage [9] and ăN=C=S linkage [10] has been well 
stressed and reported to be responsible for various biological 
activities in many compounds containing sulphur, such as 
dithiocarbamates, thiourea and thiosemicarbazides [11]. In a 
previous investigation on isothiosemicarbazone derivatives an 
interesting activity against both fungi and bacteria has been shown 
[12ă15]. Prompted by the observed biological activities of the above 
mentioned derivatives we have designed and synthesized some 
structurally new thiosemicarbazide derivatives, bearing cycloalkane, 
thiol and azomethine functionality in the same molecule, as 
antifungal and antibacterial agents. Influence of structural changes 
has been investigated and on the basis of the obtained data some 
structureăactivity relationships have been pointed out. 
Materials and methods 
Antifungal susceptibility testing  
Evaluations of the susceptibility of fungal strains were performed 
using macro tube dilution method as per NCCLS guidelines [16]. The 
fungi used as inocula were grown overnight on sabouraud dextrose 
agar (SDA) at 25μ1ĈC. To 5ml of SDA, 0.2 ml of culture was added 
and inoculated followed by incubation till it reached the turbidity 
equal to that of the standard 0.5 McFarland solution in 0.9 % 
(w/v)NaCl at 600nm which was equivalent to 106ă 108 CFU/ml. A 
stock solution of 10 mg/mL was prepared in dimethyl sulfoxide 
(DMSO, Sigma) for the various synthesized compounds and for 
fluconazole (FLC) and griseofulvin (GRS), which were used as 
control. Two fold dilutions of test compounds from 64 to 0.25 μg/mL 
were prepared with the suspension of the inoculum. The micro 
dilution tubes, which contained 0.1 mL of the serially diluted drug, 
were inoculated with 0.1 mL of the resulting suspension. The final 
inoculum concentration after dilution with the drug suspension was 
103/104 cells per mL. Two tubes containing the drug-free medium 
and inoculum were used as controls. The inoculated tubes were 
incubated at 35μ1 ĈC for 48h (Candida sp.) and 72 h (A. niger) in 
ambient air. The growth in each tube was then visually estimated. 
The minimum inhibitory concentrations (MIC) were determined 
visually, and were defined as the lowest concentration of a 
compound that inhibits growth of the organism as detected visually. 
Antibacterial activity  
Evaluations of the susceptibility of bacterial strains were made by the 
macro tube dilution method as per NCCLS guidelines [16]. Mueller-
Hinton broth was used as the test medium. An inoculum of 
approximately  5x105 CFU cm-3 was used. Serial twofold dilutions of 
the test compounds (64- 0.25 μg/mL) and extra dilutions (0.12-0.015 
μg/mL) for antibiotic standard was prepared. Tubes were incubated 
for 24hrs at 37μ1ĈC in an ambient air incubator. The lowest 
concentration of the test compounds inhibiting visible growth was 
taken as the MIC value.  
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Molecular modeling 
Insilico homology modeling of 14-đ sterol demethylase 
(CYP51) of A. fumigatus 
The 3D structure of the CYP51 from fungus Aspergillus fumigates 
(AFCYP51) have been constructed through homology modeling. 
Homology modeling or comparative modeling is predicting the 
protein 3D structure with the help of a close or homologue or known 
structure from the same family of the target protein. Amino acid 
sequences retrieved from swissprot/uniprot, provided descriptions of 
a non redundant set of proteins including their function, domain 
structure, posttranslational modifications and variants. Sequence of 
CYP51 of A. Fumigatus (AFCYP51) protein sequence (Accession 
num: AAK736590) was obtained from National Centre for 
Biotechnology Information (NCBI) as query sequence with total 
length of  461 amino acid. The selection of active site residues in the 
reference protein (MT-CYP51), was done by identifying residues in 
the substrate binding cavity and within 8 AĈ from the heme as 
depicted in literature [17]. 
Template for modeling 
Standalone blastp search was performed for finding similar structure 
entry in PDB database from ftp download available on 
ftp://ftp.ncbi.nih.gov/blast/db/FASTA/pdbaa.gz. A pair wise alignment 
has been performed using Blastp [18] against the target sequence of 
CYP51 of A. Fumigatus(AFCYP51).X-ray crystal structure of CYP51 
(Pdb Code: 3LD6) selected for backbone alignment with domains 
identified in secondary structure studies determined, available on 
http://www.rcsb.org/pdb/explore/explore.do?structureId= 3LD6. 
Comparative modeling 
For modeling AFCYP51, ICM Molsoft has been adopted. ICM 
Molsoft algorithm contains robust modeling tools and high levels of 
accuracy with fast model building [19]. After initial alignment of query 
polypeptide chain on template backbone, side chain torsion angles 
were optimized using simultaneous global optimization of the energy 
for all non-identical residues. ICM Biased Probability Monte Carlo 
(BPMC) optimization facilitates conformational modeling through 
defining internal coordinates [20]. Extensive force field terms are 
conjoined and side entropy parameters proved ICM towards 
accuracy acceptance in CASP2 protein modeling competition [21, 
22].Sequence of AFCYP51 is aligned on backbone of 3LD6 structure 
and comparative modeling was performed in ICM Molsoft. Energy 
minimization for modeled structure thermodynamically proved by 
accepted structure with energy of -26693.057 KJ/Mol and RMS value 
0.30A0.  
Structure validation using PROCHECK and standard 
drug FLC 
Structure validation of enzyme structure modeled above is 
processed using PROCHECK which determine stereochemical 
aspects along with main chain and side chain parameters with 
comprehensive analysis [23]. Optimization and analysis of bond 
length and bond angles is referred from Cambridge Structural 
Database, CSD after studying 100,000 structures [24]. Main-chain 
parameters and side-chain parameters calculated at 2.0 Ang. of 
resolution signifies modeling of AFCYP51. Distances from planarity 
is found below 0.02 when plotted against amino acids frequency in 
sequence. The 3D modeled structure is validated by docking an X-
ray structure of crystal structure of CYP51 from Leishmaniainfantum 
in complex with FLC (pdb code 3L4D).  
Molecular docking  
MolDock (MVD), based on a new heuristic search algorithm that 
combines differential evolution with a cavity prediction algorithm, was 
used for docking studies [25]. The hydrogens and bond orders were 
assigned to both ligand and protein molecules using automatic 
preparation function in MVD (grid resolution 0.20A■). For each 
complex, charges and protonation states were assigned using 
docking scoring function, and all acyclic single bonds were set as 
flexible, except for bonds that only rotated hydrogens. During the 
docking experiments, structural water molecules were excluded. The 
population size, maximum iterations, scaling factor, and crossover 
rate were set to 50, 2000, 0.50, and 0.90, respectively. The highest 
ranked solution was compared with the known experimental 
structure using the standard Cartesian root-mean-square deviation 
(RMSD) measure (between similar atoms in the pose and 
experimental structure). Similar poses were clustered depending 
upon an RMSD threshold of 1.00A■. The saved pose for the ligandă
enzyme complex of each molecule was subjected to detailed 3D 
analysis for interactions at the enzyme active site. Structural 
illustrations were created by Molegro Virtual Docker under the 
ÂWindows XPÊ operating system installed on an Intel Core 2 duo 
processor PC with a 2.8 MHz processor and 3GB RAM. The 
selection of active site residues in the reference protein (MT-CYP51), 
was done by identifying residues in the substrate binding cavity and 
within 8 AĈ from the heme as per literature [26]. Putative active site 
residues in AFCYP51 were identified as Y107, L128, M129, E130, 
K133, F134, I135, L190, L290, M292, A293, G294, H296, S297, 
S300, I301, W304, H361, S362, S363, I364, S496.The structural 
models of selected 14 compounds with MICs, 2-16 μg/mL, were 
docked into the active site of the generated homology model of 
AFCYP51. 
Synthesis 
All reagents were purchased from Sigma- Aldrich and were used 
without further purification. All melting points of synthesized 
compounds were determined by open capillary method and are 
uncorrected. IR spectra were recorded with Shimadzu FT-IR-8400S 
spectrophotometer on KBr. Elemental analysis (%C, %H, %N, %O 
and %S) of the synthesized compounds were done on CorloErba 
1108 Heracus instrument at Central Drug Research Institute (CDRI), 
Lucknow, India. The 1H and 13C NMR spectra were recorded on an 
Advance - 400 MHz Bruker, using TMS as an internal reference and  
mass spectra were obtained on a JMS-T100LC, Accu TOF 
(DARTMS)spectrophotometer at CDRI.  
Synthesis of N-(3-substituted phenyl)-3-cycloalkylidene-
thiosemicarbazide (1-3) 
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In a flask equipped with a reflux condenser, a mixture of 
cycloalkanone (0.018mol) and thiosemicarbazide (0.016 mol) were 
reacted in 80 ml of isopropyl alcohol in presence of catalytic amount 
of acetic acid. The suspension is refluxed until complete dissolution 
(30-90 mins). After completion of reaction, the reaction mixture was 
allowed to cool down to room temperature. The product is obtained 
as crystalline solid which is recrystallized from ethanol/ water-ethanol 
[27, 28]. 
N-(3-chlorophenyl)-3-cyclohexylidene-thiosemicarbazide 
(1) 
IR ѵ cm-1: 3383(NH); 3261 (NH); 3138 (CH); 2871 (CH); 1661 (C=S); 
1607(C=N); 1445 (N-N); 830(C-Cl); 789,854 (Substituted Ar). 1H 
NMR (DMSO-d6, 300 MHz, ppm):    1.2-1.3(p, 2H, CH2); 1.7-1.8 (p, 
4H, CH2), 1.9-2.0(t, 4H, CH2); 2.8 (s, NH); 7.0 (s, NH); 7.2-7.4 (Ar-
H).13C NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): Ē 187.94 
(C=S);152.40(C=N);135.78 (ar-C-N); 131.22(Ar- C-Cl); 130-112.22 
(Ar-4C); 77.32, 76.69, 34.07, 24.54, 22.65 (CH2). Mass m/z: 281.07 
(M+). Anal.Calcd. For C13 H16 N3 S Cl (281.80): Calcd.:C, 55.41; H, 
5.72; N, 12.58; S, 11.38; Found:C, 55.43; H, 4.69; N, 15.07; S, 
11.18. 
N-(3-chlorophenyl)-3-cyclopentylidene-thiosemicarbazide 
(2) 
IR ѵ cm-1: 3280, 3178(NH ); 2989-2868 (CH),1575(C=S);1500(C=N); 
1444(N-N);745 (C-Cl); 705,883 (Substituted Ar). 1H NMR (DMSO-d6, 
300 MHz, ppm):  Ē 1.4-1.8 (q, 4H, CH2); 1.9-2.0(t, 4H, CH2); 2.2 (s, 
NH); 7.0 ( s, NH); 7.2-7.5 (Ar-H).13C NMR (DMSO-d6, 75.4 MHz, 
ppm, DEPT): Ē 188.26 (C=S);152.19(C=N);135.87 (ar-C-N); 131.28 
(Ar- C-Cl); 130.06-109.94 (Ar-4C);  77.32, 76.69, 39.34, 32.01, 
22.67(CH2).  Mass m/z: 368 (M+). Anal.Calcd. For C12 H14 N3 S Cl 
(267.78): Calcd.:C 53.82, H- 5.27, N-15.69, S-11.97; Found: C 
53.64, H-5.14, N-15.61, S- 11.60. 
N-(3-Chlorophenyl)-3- 
cycloheptylidenethiosemicarbazide(3) 
IR ѵ cm-1: 3080, 3058 (NH Ar); 2989-
2937(CH),1575(C=S);1500(C=N); 1444(N-N);940 (C-Cl); 756, 790 
(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm):  1.2 (q, 8H, 
CH2), 1.5(t, 4H, CH2); 1.6(s, NH); 7.0 (s, NH); 7.4-7.5 (Ar-H). 13C 
NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): Ē 188.25 
(C=S);156.12(C=N);135.88 (ar-C-N); 131.28 (Ar- C-Cl); 130.06-
109.94 (Ar-4C); 77.32, 77.00, 76.69,42.31, 37.98, 32.12(CH2). Mass 
m/z:296 (M+). Anal.Calcd. For C14 H18 N3 S Cl (295.83): Calcd.: C 
56.84, H- 6.13, N-14.20, S-10.84; Found:C 49.61, H-4.25, N-16.83, 
S- 12.48 
Synthesis of N-(substituted -benzylidine amine)-3-
cycloalkylidine-thiosemicarbazide (4-27) 
A mixture of cycloalkylidinethiosemicarbazide (0.01mol) and an 
aromatic aldehyde (0.01 mol) and methanol (20 mL) with few drops 
of glacial acetic acid was refluxed for 3-4 hrs. The reaction mixture 
was then cooled to room temperature and kept overnight. The 
separated solid was filtered out, washed with methanol dried and 
crystallized with mixture of ethanol and acetic acid to obtain pure 
compound [29]. 
N-(3-nitrobenzylidineamine)-3-cyclopentylidine-
thiosemicarbazide (4) 
IR ѵ cm-1: 3490 (NH); 3158-3090 (Ar-CH); 2809-2975 (CH); 1602 
(C=N); 1068 (C=S); 1349, 1535 (N-O); 1472 (N-N); 937(C-N); 703, 
844 (m-substitution at Ar ring). 1H NMR (DMSO-d6, 300 MHz, ppm):  
Ē 2.5 (q, 4H,CH2); 3.3(t, 4H,CH2); 7.6(s, N=CH); 8.1-8.3(m, Ar-H); 
11.67 (s, NH). 13C NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): 
178.32(C=S); 148.41(C=N);137.94 (=CH); 139.93, 136.22, 133.20, 
130.16, 123.98, 121.42 (Ar-C(6); 40.34, 40.07, 39.79, 39.51, 
39.23(CH2). Mass m/z: 291(M+). Anal.Calcd. For C13H14N4O2S 
(290.34): Calcd.:C, 53.78; H, 4.86; N, 19.30; O,11.02; S, 11.04; 
Found: C, 53.92; H, 4.61ee; N, 19.17; O,11.23 ; S, 11.2. 
N-(4-chlorobenzylidine amine)-3-cyclopentylidine-
thiosemicarbazide (5) 
IR ѵ cm-1: 3480 (NH); 3166-3023(Ar-CH),;2976-2871 (CH); 
1600(C=N); 1368(C-N-C); 1091 (C=S); 1017(C-Cl); 830-946 
(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): 1.2 (q, 8H, 
CH2), 1.5(t, 4H, CH2); 1.6(s, NH); 7.0 (s, NH); 7.4-7.5 (Ar-H). 13C 
NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): 178.06(C=S); 
140.58(C=N);134.94(C-Cl); 133.70 -128.75 (Ar-C); 40.07, 39.79, 
39.51, 39.23(CH2). Mass m/z: 280(M+). Anal.Calcd. ForC13 H14 N3 S 
Cl (279.79): Calcd.:C, 55.81; H, 5.04; N, 15.02; S, 11.46; Found: C, 
55.97; H, 5.25; N, 15.46; S, 11.83. 
N-(2-nitrobenzylidineamine)-3-cyclopentylidine-
thiosemicarbazide (6) 
IR ѵ cm-1: 3468 (NH); 3108-3023(Ar-CH);  2955-2976 (=CH); 1601 
(C=N); 1058 (C=S); 1332, 1527 (N-O); 1472 (N-N); 1362(C-N-C); 
915(C-N  for nitro Ar); 709-856 (Substituted Ar). 1H NMR (DMSO-d6, 
300 MHz, ppm): Ē 1.2(q, 4H, CH2); 2.5 (t, CH2); 3.3(t, CH2); 7.5(s, 
N=CH); 8.1-8.3(m, Ar-H); 11.74 (s, NH). 13C NMR (DMSO-d6, 75.4 
MHz, ppm, DEPT): 178.45(C=S); 148.29(C=N); 137.18-124.53 (Ar-
C(6); 48.43, 40.33, 39.50, 38.66 (CH2). Mass m/z: 391(M+). 
Anal.Calcd. For C13 H14 N4 S O2 (290.34): Calcd.: C, 53.78; H,4.86; 
N, 19.30; O, 11.02; S,11.04; Found:C, 53.51; H,4.62; N, 19.37; O, 
11.23; S,11.18. 
N-(2-hydroxybenzylidineamine)-3-cyclopentylidine-
thiosemicarbazide (7) 
IR ѵ cm-1: 3550(C-OH); 3456 (NH); 3110-3022(Ar-CH); 2959-2981 
(=CH); 1604 (C=N); 1056 (C=S); 1343, 1557 (N-O); 1472 (N-N), 
917(C-N for nitro Ar); 705-846 (Substituted Ar). 1H NMR (DMSO-d6, 
300 MHz, ppm): Ē 1.2(m, 2H, CH2); 2.5 (m, 2H, CH2); 3.3(t, 4H, CH2); 
6.7(s, N=CH);7.5-8.3(m, Ar-H); 9.8 (s, OH); 11.22 (s, NH). 13C NMR 
(DMSO-d6, 75.4 MHz, ppm, DEPT): 177.44(C=S); 159.22(Ar-C-OH); 
142.67(C=N); 129.00-115.5 (Ar-4C), 40.35, 39.79, 39.24, 38.96 
(CH2). Mass m/z: 262 (M+). Anal.Calcd. For C13 H15 N3 S O(261.34): 
Calcd.: C, 59.74; H, 5.79; N, 16.08; O, 6.12; S, 12.27; Found: C, 
59.57; H, 5.45; N, 16.21; O, 6.24; S, 12.31. 
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N-(Imidazolidineamine)-3-cyclopentylidine-
thiosemicarbazide(8) 
IR ѵ cm-1: 3230-3134 (NH); 3010-2994(Ar-CH); 2876-2957 (CH); 
1586, 1868 (C=N); 1103 (C=S); 1472 (N-N); 1301(C-N-C). 1H NMR 
(DMSO-d6, 300 MHz, ppm): Ē 1.7(t, 2H, CH2); 1.9 (t, 2H, CH2); 2.5 (t, 
4H, CH2); 7.1(s, N=CH);7.8-8.3(m, Ar-2H);12.49 ( s, NH), (9.8 (s, 
NH), 11.55 (s, NH). 13C NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): Ē 
178.42(C=S);  155.67(C=N); 146.32(C=N); 132.23-119.24( hetcyc-C 
(3); 39.35, 29.73, 26.34, 26.56(CH2). Mass m/z: 236 (M+). 
Anal.Calcd. ForC10 H13 N5 S (235.31): Calcd.: C, 51.04; H, 5.57; N, 
29.76; S, 13.63; Found: C, 51.32; H, 5.45; N, 29.41; S, 13.90. 
N-(4-Methyl-thiazol-2-ylmethylene)-3-cyclopentylidine-
thiosemicarbazides(9) 
IR ѵ cm-1: 3454(NH); 3148-3077(Ar-CH); 2976-2831(CH); 1602 
(C=N); 1110(C=S); 1457 (N-N); 1338 (C-N-C); 705-838 (Substituted 
Ar).1H NMR (DMSO-d6, 300 MHz, ppm): Ē 1.9(s, 3H, CH3); 2.3-2.5 (t, 
4H, CH2); 3.3 (t, 4H, CH2); 7.3(s, N=CH),8.2(Ar-2H);11.68 (s, NH). 
13C NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): 178.10(C=S); 
162.82(C=N); 153.29(C=N); 136.89(2C-hetcyc); 116.31( CH3-C-
hetcy) 40.36, 39.80, 39.25, 38.97(CH2); 16.60(CH3). Mass m/z: 267 
(M+). Anal.Calcd. For C11 H14 N4 S2 (266.39): Calcd.: C, 51.04; H, 
5.57; N, 29.76; S, 13.63; Found:C, 51.23; H, 5.69; N, 29.65; S, 
13.79. 
N-(4-dimethyl-benzylamine)-3-
cyclopentylidenethiosemicarbazides (10) 
IR ѵ cm-1: 3453(NH); 3110, 3011(Ar-CH); 2901-2884(CH); 1597 
(C=N); 1148(C=S); 1459 (N-N); 1336(C-N-C); 1283 (C-N- 
dimethamine); 810, 875 (Substituted Ar). 1H NMR (DMSO-d6, 300 
MHz, ppm): Ē 2.5(q, 4H, CH2); 2.9 (s, 6H); 3.3 (t, 4H, CH2); 6.6(s, 
N=CH);7.5-7.9(Ar-6H); 11.15 (s, NH). 13C NMR (DMSO-d6, 75.4 
MHz, ppm, DEPT): Ē 2.5(q, 4H, CH2); 2.9 (s, 6H); 3.3 (t, 4H, CH2); 
6.6(s, N=CH);7.5-7.9(Ar-6H); 11.15 (s, NH). Mass m/z: 289 (M+).  
Anal.Calcd. For C15 H20 N4 S (288.41): Calcd.: C, 62.47; H, 6.99; N, 
19.43;  S, 11.12; Found:C, 62.42; H, 6.52; N, 19.37;  S, 11.28. 
N-(2-chlorobenzylidine amine)-3-cyclopentylidine-
thiosemicarbazide (11) 
IR ѵ cm-1: 3430 (NH); 3155-3112(Ar-CH); 2983-2793 (CH); 
1611(C=N); 1374(C-N-C); 1103 (C=S); 1047(C-Cl); 821-
869(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 2.5 (m, 
4H, CH2); 3.1-3.3(t, 4H,CH2); 7.3(s, N=CH);8.4- 8.1(m, Ar-H); 11.63 
(s, NH). 13C NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): 178.22(C=S); 
138.15(C=N);133.12(N=CH); 131.49-127.35(Ar-6C); 40.35, 39.80, 
39.24, 38.96 (CH2). Mass m/z: 280 (M+). Anal.Calcd. ForC13 
H14ClN3 S (279.79): Calcd.: C, 55.81; H, 5.04; N, 15.02; S, 11.46; 
Found:C, 55.54; H, 5.12; N, 15.33; S, 11.32.  
N-(3-nitrobenzylidineamine)-3-cyclohexylidine-
thiosemicarbazide (12) 
IR ѵ cm-1: 3397 (NH); 3160-3094(Ar-CH); 2812-2986 (CH); 1603 
(C=N); 1069 (C=S); 1348 (C-N-C); 1537 (N-O); 1471 (N-N); 937(C-
N); 704, 844 (Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 
1.2-1.3 (t, 2H, CH2); 2.5 (q, 4H, CH2); 3.3(t, 4H, CH2); 7.6(s, N=CH); 
8.1-8.6(m, Ar-H); 11.61 (s, NH). 13C NMR (DMSO-d6, 75.4 MHz, 
ppm, DEPT): 178.33(C=S); 148.38(C=N);139.89 (N=CH ); 136.18, 
133.52, 130.10, 123.91, 121.36 (Ar-6C);  40.34, 40.06, 39.79, 39.51, 
39.23, (CH2).  Mass m/z: 305 (M+). Anal.Calcd. For C14 H16 N4O2 S 
(304.37): Calcd.: C, 55.25; H, 5.30; N, 18.41; S, 10.53; O, 10.51; 
Found: C, 55.67; H, 5.56; N, 18.34; S, 10.89; O, 10.32. 
N-(4-chlorobenzylidine amine)-3-
cyclohexylidenethiosemicarbazide (13) 
IR ѵ cm-1: 3438 (NH); 3165-3025(Ar-CH); 2994-2887 (CH); 
1600(C=N); 1490 (N-N); 1091 (C=S); 1367(C-N-C); 1017(C-Cl); 700-
830 (Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm):Ē 1.2-1.3 
9t, 2H, CH2); 2.5 (q, 4H, CH2); 3.1-3.3(t, 4H,CH2); 7.4(s, N=CH); 7.7-
8.7(m, Ar-H); 11.48 (s, NH).13C NMR (DMSO-d6, 75.4 MHz, ppm, 
DEPT): 178.07(C=S); 134.21 (C=N);140.81 (N=CH); 133.19(Ar-C-
Cl); 128.94-128.68(Ar-6C); 40.34, 39.78, 39.51, 39.23, 38.95 (CH2). 
Mass m/z: 294 (M+). Anal.Calcd. For C14 H16 Cl N3 S (293.81): 
Calcd.: C, 57.23;  H, 5.49;  N, 14.30; S, 10.91; Found:C, 57.57; H, 
5.25; N, 14.46; S, 10.83. 
N-(2-nitrobenzylidineamine)-3-
cyclohexylideneylidinethiosemicarbazide (14)  
IR ѵ cm-1: 3450 (NH); 3151-3083(Ar-CH); 2975-2800 (CH); 1601 
(C=N); 1125 (C=S); 1333, 1539 (N-O); 1472 (N-N); 1311(C-N-C); 
916(C-N); 705-850 (Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, 
ppm): Ē 1.2(t, 2H, CH2); 2.5-2.6 (m, 4H,CH2); 2.9-3.3(t, 4H, CH2); 
7.4(s, N=CH); 7.7-8.7(m, Ar-H); 11.742(s, NH). 13C NMR (DMSO-d6, 
75.4 MHz, ppm, DEPT): 178.49(C=S); 148.29(HC=N); 137.22 (C=N); 
133.34(C-NO2); 130.36-124.50 (Ar-5C); 40.35, 40.07, 39.79, 38.96, 
38.68 (CH2). Mass m/z: 305 (M+). Anal.Calcd. For C14 H16 N4O2 S 
(304.37): Calcd.: C, 55.25; H, 5.30; N, 18.41; O, 10.51; S, 10.53; 
Found:C, 55.45; H, 5.49; N, 18.98; O, 10.12; S, 10.29. 
N-(2-hydroxybenzylidineamine)-3-
cyclohexylidenethiosemicarbazide (15)  
IR ѵ cm-1: 3578 (OH); 3456 (NH); 3151-3014(Ar-CH); 2808-2981 
(CH); 1598 (C=N); 1056 (C=S); 1376, 1554 (N-O); 1461(N-N);1305 
(C-N-C); 917(C-N); 904 -947(Substituted Ar). 1H NMR (DMSO-d6, 
300 MHz, ppm): Ē 1.3 (t, 2H, CH2); 2.5 (q, 4H, CH2); 3.3(t, 4H);  
6.7(s, N=CH); 7.5-8.0(m, Ar-H); 9.8 (s, OH); 11.26 (s, NH). 13C NMR 
(DMSO-d6, 75.4 MHz, ppm, DEPT): 177.42(C=S); 159.27(Ar-C-OH); 
142.71(HC=N); 129.09(C=N); 125-115.5 (Ar-C); 40.34, 39.79, 39.51, 
38.96, 38.68 (CH2). Mass m/z: 276 (M+).Anal.Calcd. For C14 H17 N3 
SO (275.37):  Calcd.: C, 61.06; H, 6.22; N, 15.26; O, 5.81; S, 11.64; 
Found:C, 61.23; H, 6.16; N, 15.51; O, 5.78; S, 11.41. 
N-(imidazolidineamine)-3-cyclopentylidine-
thiosemicarbazide (16) 
IR ѵ cm-1: 3460, 3271 (NH); 3085, 3046(Ar-CH); 2928 (CH); 1623, 
1594 (C=N); 1089 (C=S); 1456 (N-N); 1306(C-N-C); 793, 847 
(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 1.6(t, 2H, 
CH2); 2.5(q, 4H, CH2); 3.3(t, 4H, CH2); 7.0(s, N=CH); 7.0-8.3(m, Ar-
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H); 11.57(s, NH); 12.50 (s, Cyclic NH). 13C NMR (DMSO-d6, 75.4 
MHz, ppm, DEPT): 177.23(C=S), 154.56(C=N), 145.34(C=N), 
131.23-118.23(hetcyc-C(3), 38.35, 34.73, 29.34, 28.23, 26.56 (CH2). 
Mass m/z: 250 (M+). Anal.Calcd. For C11H15N5S (249.34): Calcd.: C, 
52.99; H, 6.06;  N, 28.09; S, 12.86; Found: C, 52.87; H, 6.26;  N, 
28.19; S, 12.67.   
N-(4-Methyl-thiazol-2-ylmethylene)-3-
cyclohexylidenethiosemicarbazides(17) 
IR ѵ cm-1: 3445(NH); 3224-48-3078( hetcyc-CH); 2981-2857(CH); 
1603, 1592 (C=N); 1112(C=S); 1457 (N-N); 1336(C-N-C); 764, 838 
(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 1.9(s, 3H, 
CH3); 2.3 (t, 2H, CH2); 2.5 (q, 4H, CH2); 3.3 (t, 4H, CH2); 7.3(s, 
N=CH);8.4-8.2(s, Hetcyc-H); 11.70 (s, NH). 13C NMR (DMSO-d6, 
75.4 MHz, ppm, DEPT): 178.07(C=S); 162.87(C=N); 153.32(C=N); 
136.92(2C-hetcyc); 116.31( C-hetcy); 40.35, 39.79, 39.23, 
38.96,38.68(CH2); 16.66(CH3). Mass m/z: 281 (M+).  Anal.Calcd. For 
C12H16  N4 S2 (280.41): Calcd.: C, 51.40; H, 5.75; N, 19.98;  S, 
22.87; Found: C, 51.67; H, 5.89; N, 19.76;  S, 22.97. 
N-(4-dimethyl-benzylamine)-3-
cyclohexylidenethiosemicarbazides (18) 
IR ѵ cm-1: 3459(NH); 3138(Ar-CH); 2989-2854(CH); 1595, 1587 
(C=N); 1126(C=S); 1464 (N-N); 1339(C-N-C); 1278 (C-N, dimethyl 
amine); 820, 878 (Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, 
ppm): Ē 2.5(t, 2H, CH2); 2.9 (s, 6H, CH3); 3.1(q, 4H, CH2), 3.3 (t, 4H, 
CH2); 6.6(s, N=CH);7.5-8.0(Ar-6H);11.18 (s, NH). 13C NMR (DMSO-
d6, 75.4 MHz, ppm, DEPT): 176.99(C=S); 151.38(C=N); 
143.32(C=N); 128.62-111.69(Ar-6C); 47.15(CH3), 40.35, 40.07, 
39.79, 39.51, 39.24(CH2). Mass m/z:  303 (M+).  Anal.Calcd. For C16 
H22N4S (302.44): Calcd.: C, 63.54;  H, 7.33; N, 18.53; S, 10.60; 
Found:C, 63.87;  H, 7.53; N, 18.51; S, 10.32. 
N-(2-chlorobenzylidine amine)-3-cyclopentylidine-
thiosemicarbazide (19) 
IR ѵ cm-1: 3340 (NH); 3179-3125(Ar-CH); 2983-3022 (CH); 1610, 
1594(C=N); 1375(C-N-C); 1103 (C=S); 1046(C-Cl); 710-
869(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 1.9(q, 
2H, CH2); 2.5 (q, 4H, CH2); 3.3(t, 4H,CH2); 7.3(s, N=CH);8.4- 8.1(m, 
Ar-H); 11.65 (s, NH). 13C NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): 
178.21(C=S); 138.15(HC=N);133.13( N=C);  131.49-127.35(Ar-6C); 
40.35, 39.79, 39.51, 38.68, 35.21(CH2). Mass m/z:  294 (M+). 
Anal.Calcd. For C14 H16 Cl N3 S (293.91): Calcd.: C, 57.23; H, 5.49; 
N, 14.30;  S, 10.19; Found:C, 57.67; H, 5.82; N, 14.43;  S, 10.21. 
N-(3-nitrobenzylidineamine)-3-
cyclohepylidenethiosemicarbazide (20) 
IR ѵ cm-1: 3383, 3238 (NH); 3192-3091(Ar-CH); 2810-2987 (CH); 
1603 (C=N); 1069 (C=S); 1349 (C-N-C); 1528 (N-O); 1471 (N-N); 
937(C-N nitroaromatic compounds); 703, 820 (Substituted Ar). 1H 
NMR (DMSO-d6, 300 MHz, ppm): Ē 2.5 (m, 6H, CH2); 3.3(t, 4H, 
CH2); 7.6(s, N=CH); 8.1-8.6(m, Ar-H); 11.59 (s, NH). 13C NMR 
(DMSO-d6, 75.4 MHz, ppm, DEPT): 178.36(C=S); 148.39(HC=N); 
139.91 (N=C); 136.18, 133.50, 130.10, 123.91, 121.36 (Ar-6C); 
40.35, 40.07, 39.79, 39.51, 39.24, 38.96(CH2). Mass m/z:  319 (M+). 
Anal.Calcd. For C15 H18 N4 O2 S (318.39): Calcd.: C, 56.58; H,5.70; 
N,17.60; S,10.05; O,10.07; Found:C, 56.25; H,5.87; N,17.34; 
S,10.14; O,10.32.  
N-(4-chlorobenzylidine amine)-3-
cycloheptylidenethiosemicarbazide (21) 
IR ѵ cm-1: 3423, 3273(NH); 3158-3056(Ar-CH); 2995-2772 (CH); 
1610(C=N); 1490 (N-N); 1091 (C=S); 1367(C-N-C); 1017(C-Cl); 700-
830 (Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 2.5 (q, 
6H, CH2); 3.3(t, 4H, CH2); 7.4(s, N=CH); 8.2-7.8(m, Ar-H); 11.49 (s, 
NH). 13C NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): 178.07(C=S); 
134.26 (C=N);140.86 (N=CH); 133.23(Ar-C-Cl); 128.99-128.73(Ar-
6C); 40.34, 39.79, 39.51, 39.23, 38.95,38.67(CH2). Mass m/z:  308 
(M+). Anal.Calcd. For C15 H18Cl N3 S (307.84): Calcd.: C, 58.52; H, 
5.89; N, 13.65;  S, 10.42; Found: C, 58.76; H, 5.97; N, 13.32;  S, 
10.30. 
N-(2-nitrobenzylidineamine)-3-
cycloheptylidenethiosemicarbazide (22) 
IR ѵ cm-1: 3458 (NH); 3228-3107 (Ar-CH); 3083-2974 (CH); 1601 
(C=N); 1105 (C=S); 1334, 1541 (N-O); 1471 (N-N); 1311(C-N-C); 
930(C-N strvib for nitroaromatic compounds); 722-849 (Substituted 
Ar). 1H NMR (DMSO-d6, 300 MHz, ppcm): Ē 2.5 (m, 8H, CH2); 3.3(t, 
4H, CH2); 7.6(s, N=CH); 7.7-8.4(m, Ar-H); 11.73(s, NH). 13C NMR 
(DMSO-d6, 75.4 MHz, ppm, DEPT): 178.47(C=S); 148.30(HC=N); 
137.21(C=N); 133.36(C-NO2); 130.36-124.53 (Ar-5C); 40.34, 40.07, 
39.79, 39.51, 38.96, 38.68 (CH2). Mass m/z:  319 (M+). Anal.Calcd. 
For C15 H18 N4O2 S (318.39): Calcd.: C, 56.58,;H, 70.01; N,17.60; O, 
10.05; S, 10.07; Found: C, 56.39,;H, 70.12; N,17.69; O, 10.06; S, 
10.13. 
N-(2-hydroxybenzylidineamine)-3-
cycloheptylidenethiosemicarbazide (23) 
IR ѵ cm-1: 3580 (OH); 3457(NH); 3127-3003(Ar-CH); 2806-2948 
(CH); 1608, 1585 (C=N); 1097 (C=S); 1374, 1547 (N-O); 1445(N-N); 
1307(C-N-C); 822, 834 (Substituted Ar). 1H NMR (DMSO-d6, 300 
MHz, ppm): Ē 2.5 (m, 8H, CH2);  3.1-3.3(t, 4H, CH2); 6.7(s, N=CH); 
7.5-8.0(m, Ar-H); 9.84 (s, OH); 11.22 (s, NH). 13C NMR (DMSO-d6, 
75.4 MHz, ppm, DEPT): 177.44(C=S); 159.22(Ar-C-OH); 
142.68(HC=N); 129.01(C=N); 125-115.51 (Ar-C); 40.34, 39.78, 
39.51, 39.23, 38.95, 38.67(CH2). Mass m/z:290 (M+). Anal.Calcd. 
For C15 H19 N3O S (289.40): Calcd.: C, 62.25; H, 6.62; N, 14.52; O, 
5.53; S,11.08; Found: C, 62.56; H, 6.78; N, 14.34; O, 5.78; S,11.10. 
N-(imidazoledineamine)-3-cyclopentylidine-
thiosemicarbazide (24) 
IR ѵ cm-1: 3360, 3250 (NH); 3044, 3006(Ar-CH); 2999-2803 (CH); 
1588 (C=N); 1097 (C=S); 1455(N-N); 1290(C-N-C); 794, 839 
(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 1.5-1.6(m, 
4H, CH2); 2.5(m, 4H, CH2); 3.3(t, 4H, CH2); 7.0(s, N=CH); 7.4-8.5(m, 
Ar-H); 9.7 (s, NH); 12.50 (s, Cyclic NH). 13C NMR (DMSO-d6, 75.4 
MHz, ppm, DEPT): 177.54(C=S); 157.23(C=N); 144.43(C=N); 
133.23-114.34(hetcyc-C(3); 38.32, 34.75, 29.44, 27.16(CH2). Mass 
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m/z:  264 (M+).  Anal.Calcd. For C12 H17 N5 S (263.36): Calcd.: C, 
54.73; H, 6.51;N, 26.59; S, 12.18; Found: C, 54.45; H, 6.23;N, 26.66; 
S, 12.14. 
N-(4-Methyl-thiazol-2-ylmethylene)-3-
cycloheptylidenethiosemicarbazides (25) 
IR ѵ cm-1: 3490(NH); 3224-3143(hetcyc-CH); 2924-3077(CH); 1603, 
1592 (C=N); 1111(C=S); 1461 (N-N); 1336(C-N-C); 764, 838 
(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 1.9(s, 3H, 
CH3); 2.3-2.5 (m, 8H, CH2); 3.1-3.3 (t, 4H, CH2); 7.3(s, N=CH);8.4-
7.6(s, Hetcyc-H);11.72 (s, NH).13C NMR (DMSO-d6, 75.4 MHz, ppm, 
DEPT): 178.06(C=S); 162.91(HC=N);153.34(C=N); 136.94(2C-
hetcyc); 116.31( C-hetcy.CH3); 40.34, 39.79, 39.51, 39.23, 38.95, 
38.68 (CH2); 16.66(CH3). Mass m/z:  295 (M+). Anal.Calcd. For C13 
H18 N4 S2 (294.44): Calcd.: C, 53.03; H, 6.16; N, 19.03; S, 21.78; 
Found: C, 53.23; H, 6.45; N, 19.14; S, 21.95. 
N-(4-dimethyl-benzylamine)-3-
cyclohexylidenethiosemicarbazides (26) 
IR ѵ cm-1: 3489(NH); 3121, 3018 (Ar-CH); 2978-2802(CH); 1590, 
1578 (C=N); 1085(C=S); 1462 (N-N); 1309(C-N-C); 1248 (C-N, 
dimethyle amine); 810, 875 (Substituted Ar). 1H NMR (DMSO-d6, 
300 MHz, ppm): Ē 2.5(m, 8H, CH2); 2.9(s, 6H); 3.3 (t, 4H, CH2); 6.6(s, 
N=CH);7.5-7.9(Ar-6H);11.17 (s, NH). 13C NMR (DMSO-d6, 75.4 
MHz, ppm, DEPT): 176.97(C=S); 151.39(C=N);143.30(C=N); 
128.63-111.69(Ar-6C); 40.34(CH3); 40.07 (CH3); 39.79, 39.51, 
39.23, 38.96, 38.68 (CH2). Mass m/z:  317 (M+). Anal.Calcd. For C17 
H24 N4 S (316.46): Calcd.: C, 64.52; H, 7.64; N, 17.70; S, 10.13; 
Found: C, 64.66; H, 7.29; N, 17.89; S, 10.24. 
N-(2-chlorobenzylidine amine)-3-
cycloheptylidenethiosemicarbazide (27) 
IR ѵ cm-1: 3440 (NH); 3240-3151(Ar-CH); 2984-3062 (CH); 1611, 
1593(C=N); 1374(C-N-C); 1103 (C=S); 1047(C-Cl); 756-
870(Substituted Ar). 1H NMR (DMSO-d6, 300 MHz, ppm): Ē 2.5 (q, 
8H, CH2); 3.1-3.3(t, 4H, CH2); 7.3(s, N=CH);8.4- 8.1(m, Ar-H); 11.64 
(s, NH). 13C NMR (DMSO-d6, 75.4 MHz, ppm, DEPT): 
178.21(C=S);138.14(HC=N);133.13(N=C); 131.50-127.36(Ar-6C); 
40.35, 40.07, 39.79, 39.51, 38.96, 38.68(CH2). Mass m/z:  308 (M+).  
Anal.Calcd. For Calcd.: C, 58.52; H, 5.89; N, 13.65; S-10.42; Found: 
C, 58.67; H, 5.56; N, 13.32; S-10.10. 
Results and discussions 
Chemistry 
We have utilized thiosemicarbazide and cycloalkanone as two 
potential synthetic blocks and reported the synthesis of twenty seven 
cycloalkylidenethiosemicarbazides (1-27) as depicted in Scheme 1 
and scheme 2. Scheme 1 involved condensation reaction between 
substituted thiosemicarbazides and cycloalkanones resulted in to 
formation of cycloalkylidenethiosemicarbazides (1-3). Scheme 2 is 
characterized by reaction between terminal 1N of 
cycloalkylidenethiosemicarbazides and various substituted aromatic 
aldehydes and resulted in to the formation of 
cycloalkylidenethiosemicarbazide derivatives (4-27) as described in 
scheme 2.  
n(H2C)
O + NH2 NH
S
NH R
n= 1,2,3
n(H2C)
N NH C
S
NH R
(28-30)
Isopropyl alcohol
Acetic acidreflux for 30-90 mins
 
Scheme 1: Synthesis of N-(3-substituted phenyl)-3-cycloalkylidene-
thiosemicarbazides 
 
n(H2C)
N NH C
S
NH2
B1: n=1
B2: n=2
B3: n=3
glacial acetic acid
methanol
reflux for 3-4 Hrs
n(H2C)
N NH C
S
N CH
(31-54)
H
O
R
R  
Scheme 2: Synthesis of N-(substituted -benzylidine amine)-3-
cycloalkylidine-thiosemicarbazides 
 
Structures of all compounds synthesized were identified by 1H NMR, 
13C NMR, FT-IR and elemental analysis. The Infrared spectra (IR) of 
each of the synthesized compounds showed absorption bands which 
are characteristic of the anticipated structure of the synthesized 
compounds. Infrared measurements showed the presence of NH 
(3400-3600 cm-1), C=N (1580-1611 cm-1) and C=S (1010-1598 cm-1) 
stretches at their expected frequencies. Moreover, the presence of 
NO2 group in 4, 6, 12, 14, 20 and 22was indicated by the 
appearance of asymmetric and symmetric NO2 stretching bands at 
1550ă1500 cm-1 and 1365ă1335 cm-1, respectively.Compounds 1, 2, 
3, 5, 11, 13, 19, 21and 27 showed CăCl stretchings at 830-1049 cm-
1. More significantly, a 13C NMR chemical shift at 176.11-180.50 ppm 
was indicative of a C=S moiety. All the compounds exhibited 13C 
NMR chemical shift for HC=N at 133.10-158.11 ppm and for C=N at 
138.40-162.56 ppm. Cyclic protons appeared as multiplate or triplet 
between Ē 1.2-2.5 through 1H NMR.  Mass spectra of compounds (1-
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27) exhibited molecular ion peak at their expected m/z values. All NH 
protons were appeared as singlet in 1H NMR at Ē 11.2-11.5 ppm. 
Peaks at Ē 7.4-8.5 in compounds 4-27 accounted for presence of 
aromatic groups through 1H NMR which is further confirmed by the 
presence of peaks at 111.23-138.56 ppm in 13C NMR. The 13C 
spectrum corroborated the proton and IR data, clearly displaying the 
expected signals (C=S, C=O, C-O, C=N, cycloalkyl carbons (5C-7C), 
CH, CH2, and CH3). Other characterization data is cited in Table 1. 
 
Table 1: Characterization data of compounds 
N
H
N C
S
H
N
R
n(H2C)
N
N
H
C
S
N
H
C
n(H2C)
R
 
(1-3)      (4-27) 
Compound No. m.p. (ĈC) Yield (%) n R
1 147-149 76 Cyclopentyl Cl
2 123-125 66 Cyclohexyl Cl
3 122-125 55 Cycloheptyl Cl
4 159-161 72 Cyclopentyl 3-NO2-C6H4
5 169-172 69 Cyclopentyl 4-Cl- C6H4
6 210-215 51 Cyclopentyl 2- NO2-C6H4
7 189-190 61 Cyclopentyl 4-OH-C6H4
8 105-111 55 Cyclopentyl 
N
H
N
9 180-184 56 Cyclopentyl 
N
S
CH3
10 165-167 58 Cyclopentyl 4-N(CH3)2-C6H4
11 174-176 65 Cyclopentyl 2-Cl- C6H4
12 190-192 69 Cyclohexyl 3-NO2-C6H4
13 171-175 79 Cyclohexyl 4-Cl- C6H4
14 211-213 48 Cyclohexyl 2- NO2-C6H4
15 183-185 66 Cyclohexyl 4-OH-C6H4
16 128-130 68 Cyclohexyl 
N
H
N
17 181-182 59 Cyclohexyl 
N
S
CH3
18 150-154 51 Cyclohexyl 4-N(CH3)2-C6H4-
19 127-130 70 Cyclohexyl 2-Cl- C6H4
20 190-191 67 Cycloheptyl 3-NO2-C6H4
21 169-173 59 Cycloheptyl 4-Cl- C6H4
22 208-211 59 Cycloheptyl 2- NO2-C6H4
23 182-186 58 Cycloheptyl 4-OH-C6H4
24 81-83 72 Cycloheptyl 
N
H
N
25 180-182 61 Cycloheptyl 
N
S
CH3
26 159-162 74 Cycloheptyl 4-N(CH3)2-C6H4-
27 170-172 79 Cycloheptyl 2-Cl- C6H4
 
 
 
 
Vengurlekaret al. International Journal of Drug Delivery 6 (2) 99-112 [2014] 
 
PAGE | 106 |
 
Antimicrobial evaluation 
All synthesized compounds were evaluated for antifungal and 
antibacterial activity using macrotube dilution method. Fluconazole 
and griseofulvin were used as positive control for various fungal 
strains and ciprofloxacin for bacterial strains for their MIC 
determination. Preliminary assay was performed for a total of five 
fungal strains and five bacterial strains (including both gram positive 
and gram negative strains). The included fungal isolates were 
Candida albicans (2 strains: ATCC 24433, ATCC 10231, Candida 
tropicalis ATCC 13803, Aspergillusniger ATCC 9029 and 
Penicilliumchrysogenum ATCC 10002. The included bacterial 
isolates were Pseudomonas aeruginosa ATCC 9027, 
Staphylococcus aureus ATCC 6538P, Staphylococcus aureus 
ATCC 25923, Serratiamarcescens ATCC 13880,  Escherichia coli 
ATCC8739.  
Antifungal activity  
Table 2 exhibited the antifungal activity of 
cycloalkylidenethiosemicarbazide derivatives (1-27) against various 
fungal strains. Compounds 9, 14, 24 and 25 have shown 
remarkable activity (16 øg/mL) against A. niger ATCC 9029. 
Compounds6, 8, 9, 14, 19, 21 and 25 (16 øg/mL) against C. 
Albicans ATCC 24433and compounds 14 and 27 were found to be 
most active against C. Albicans ATCC 10231(8øg/mL). Some 
compounds such as 6, 8, 9, 11, 18 and 25 shown remarkable 
activity (16 øg/mL) against C. Albicans ATCC 10231. Compounds 
14 and 25 were found to be most active (8øg/mL) against Candida 
tropicalisATCC 13803. Only compounds 11 and 27 have resulted in 
to good activity (16 øg/mL) against Penicilliumchrysogenum ATCC 
10002. Among all cycloalkylidenethiosemicarbazide derivatives 
compound 14 and 27 have shown interesting activity. Compound 14 
have shown more activity (8øg/mL) than standard GRS against A. 
niger ATCC 9029 and C. albicans ATCC 10231 and shown more 
activity than standard FLC against C. tropicalis ATCC 13803. 
Compound 27 exhibited more activity than GRS against C. albicans 
ATCC 10231 and P. chrysogenum ATCC 10002. Compound 14 
was found to be most active among 
cycloalkylidenethiosemicarbazide derivatives against most of the 
fungal strains used in the study.  
 
Table 2: Antifungal activities of cycloalkyllidenethiosemicarbazide derivatives  
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Structure activity relationship 
Results of the antifungal activity (Table 2) of 
cycloalkylidenethiosemicarbazides indicated that all the compounds 
with more electron withdrawing ăCl substitution at para position (5, 
13, 21) and ortho position (11, 19 and 27) of the benzene rings 
have shown good activity against candida strains but when we 
changed the substitution from chloro to nitro (comparatively less 
electron withdrawing) at ortho position (6, 14) the activity increased 
further (except in case of cycloheptyl derivatives, 22). When we 
introduced electron donating groups e. g. ăOH, -N (CH3)2 in 
compounds 12, 15, 18 and 26 resulted in less activity. The 
presence of heterocyclic nucleus such as imidazoles and thiazoles 
in place of phenyl ring did not show any significant change in the 
activity. Phenyl ring with 3-NO2 substituent as electron withdrawing 
groups (4, 12, and 20) shown very less activity against fungal 
strains indicated that electron withdrawing groups  at meta position 
of the ring is not suitable for the activity (Fig. 1). Cycloalkylidene 
moiety shown more activity than thiourea moiety (1, 2, and 3) of 
thiosemicarbazides. 
 
 
 
Figure 1:SAR of antifungal activity of cycloalkylidenethiosemicarbazide derivatives 
 
Antibacterial activity 
All of the cycloalkylidenethiosemicarbazide derivatives were also 
tested against various bacterial strains. The data reported in Table 
3 indicated that compound 25 was found to be active (32 øg/mL) 
against Pseudomonasaeruginosa ATCC9027.  Compound 11 have 
shown moderate activity (32 øg/mL) against Staphylococcus aureus 
ATCC 25923. Some compounds 1 and 18 have shown good activity 
against Escherichia coli ATCC8739. All other compounds have 
shown antibacterial activity less than the reference drug. In general 
the compounds showed low antibacterial activity as compared to 
antifungal activity. 
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Table 3: Antibacterial activities of cycloalkylidenethiosemicarbazide derivatives  
 
Molecularmodeling 
We constructed a three-dimensional model of CYP51 from A. niger 
and investigated the active site of CYP51 through homology 
modeling. Sequence of AFCYP51 protein retrieved from NCBI and 
shown in Fig.2. X-ray crystal structure of Human Lanosteraol 14đ-
demethylase (PDB Code: 3LD6) shown 38% identity with our target 
protein (AFCYP51), Fig. 3.  
 
 
Figure 2:Crystal structure of human lanosterol 14đ-demethylase 
(Cyp51) in complex with ketoconazole (PDB: 3LD6) 
 
 
Figure 3:3D View of template in Accelerys DS Viewpro 
 
Structure validation of protein structure modelled is processed using 
PROCHECK which determined stereochemical aspects along with 
main chain and side chain parameters with comprehensive 
Compound                      *Tested bacterial strains (MIC øg/mL)
A B C D E
1 64 >64 >64 64 32
2 64 >64 64 64 >64
3 >64 >64 64 64 64
4 >64 >64 64 >64 64
5 >64 64 64 64 64
6 >64 64 64 >64 64
7 >64 >64 >64 >64 >64
8 >64 >64 >64 >64 >64
9 >64 >64 >64 >64 >64
10 >64 >64 >64 >64 >64
11 64 64 32 64 64
12 >64 >64 >64 >64 >64
13 >64 >64 >64 >64 >64
14 >64 64 64 64 64
15 64 64 64 64 64
16 64 >64 >64 >64 64
17 >64 64 64 64 >64
18 64 64 64 >64 32
19 64 >64 >64 >64 >64
20 64 >64 >64 >64 >64
21 64 64 64 >64 >64
22 64 64 64 64 >64
23 >64 >64 >64 >64 >64
24 >64 64 64 64 64
25 32 64 64 >64 64
26 >64 >64 64 64 >64
27 >64 >64 >64 >64 >64
Ciprofloxacin 8 2 2 8 16
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analysis. PROCHECK analysis revealed in Ramachandran plot 
(Fig. 4) concluding Phi and psi angles to contribute in conformations 
of amino acids excluding glycine and proline with 89.3 % (351) 
residues in most favoured region, 9.4%(34) in additional allowed 
region, 1.0%(4) in generously allowed region and 0.3%(1) residues 
in disallowed region.  
 
 
 
Figure 4: Ramchandran plot of homology-modeledCyp51, derived 
by using Deep View/Swiss-PDBViewe 
 
The generated homology structure is validated using standard drug 
FLC. The binding model obtained was fully comparable to the 
bioactive conformation of FLC into the crystallized complex, thus 
demonstrating the reliability of the selected computational 
methodology of generating 3D structure of AFCYP51. Docking of 
FLC complex as standard from PDB, reported to have good binding 
capacity with docking score 118(min) to 125.90(max) for five poses 
accompanying acceptable RMSD issues from 0.831(min) to 
5.8260(Max). FLC when docked in newly modeled structure of 
AFCYP51, active site used for all 14 candidate even yielded more 
interesting results with docking score 109(min) to 132(max) 
supported by RMSD values 1.7(min) to 9.1(max) for same five 
poses (Fig. 5). Protein sequence obtained from AFCYP51 falls in 
same position and region as described in literature. Amino acids 
found in the active site of 3D structure of AFCYP51were Met129, 
Glu130, Phe134, Ile135, Leu290, Met292, Ala293, Glu456, Cys454 
and Glu131 (Fig. 6) yielded a cavity of volume 590 AĈ and all amino 
acids found surrounding the corresponding positions in active site 
 
 
Figure 5: Hydrogen binding interactions in standard FLC with 
homology modelled structure of Protein CYP51, green lines indicate 
the hydrogen bonds 
 
 
Figure 6:The substrate 3LD6 showing the cavity 
 
Structural model of selected 14 molecules were docked on 3D 
model of AFCYP51. The values of RMSD obtained in results should 
not exceed 1.000 (according to reference ligand). When reference 
ligand is absent. It may be considered up to 2.0.Compound 11, 18 
and 25 have shown best RMSD value of 0.944, 0.725 and 0.812 
respectively and score of -83.966, -95.088 and -92.436 and shown 
poor hydrogen bonding with the target protein. Compound 11 and 
14shown reasonable RMSD and Scores (Table 4), along with 
hydrogen bonding (Fig. 7). Molecular interpretation approves that 
C=S (green coloured atoms in Fig. 7) group present in compound 
11and other similar inhibitors are critical for their antifungal activity. 
It contributes to most of the hydrogen bonding interactions in drug-
receptor binding.  
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Figure 7: Hydrogen bond interactions of compound 11 
 
Table 4: Docking scores of some cycloalkylidenethiosemicarbazide derivatives 
 
Compounds Best Pose  MolDock Score GRID MolDock score Rerank score R.M.S.D Torsions 
5 4 -91.499 -92.533 -72.420 1.001 4 
6 3 -97.134 -85.162 -67.489 3.541 5 
8 3 -94.775 -92.172 -68.052 2.304 4 
9 4 -100.273 -100.175 -72.950 4.975 4 
10 2 -94.690 -97.864 -72.953 4.960 5 
11 4 -83.966 -89.567 -71.600 0.944 4 
13 4 -90.456 -91.893 -69.818 6.086 4 
14 4 -87.899 -82.016 -64.612 1.723 5 
18 3 -95.088 -94.603 -64.205 0.735 5 
19 3 -90.313 -88.501 -73.870 1.451 5 
21 1 -93.680 -94.455 -68.334 0.012 4 
24 4 -89.208 -88.455 -69.965 4.228 4 
25 5 -92.436 -95.056 -74.937 0.812 4 
27 1 -84.963 -85.809 -71.998 1.638 4 
 
Conclusion 
A series of cycloalkylidenethiosemicarbazide derivatives were 
synthesized and screened for their antifungal activities using macro 
tube dilution method. Compound 14 with NO2 group and compound 
27 as 1N-substitution to thiosemicarbazides was found to be most 
active against most of the fungal strains used in the study and 
compound 11 & 25 shown moderate activities against fungal 
strains. Docking studies showed that compound 25 possessed 
good binding scores for fungal CYP51 in the sterol biosynthesis 
pathway. The structureăactivity relationships discussed above may 
provide useful information for further design and synthesis of 
compounds with optimized bioactivity profile. Additional studies to 
optimize the structural feature as well as to explore the mechanism 
of action and toxicity of this class of compounds are required which 
could be helpful in designing more potent antifungal agents for 
therapeutic use. 
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